1
|
Ito H, Shigeto A, Hashizume T. A solvent-free squeezing method for extraction of collected mass from aerosols of electronic cigarettes and heated tobacco products. J Chromatogr A 2024; 1727:465009. [PMID: 38776605 DOI: 10.1016/j.chroma.2024.465009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 05/10/2024] [Accepted: 05/17/2024] [Indexed: 05/25/2024]
Abstract
Previous in vitro toxicological assessments have demonstrated that almost no mutagenic and genotoxic activities in electronic cigarette (e-cigarette) and heated tobacco product (HTP) aerosols were detected even at the maximum recommended concentration. To accurately compare the toxicity levels between cigarette smoke and e-cigarette or HTP aerosols, higher exposure concentrations increasing the possibility to detect toxicity in in vitro tests are necessary, while avoiding solvent-induced toxicity. This study aimed to develop a solvent-free extraction method to obtain concentrated aerosol extracts for improved toxicological evaluation. Our novel approach involved squeezing several Cambridge filter pads, which collected aerosol constituents, in closed containers to achieve solvent-free extraction with comparable efficiency to the conventional method using organic solvents. The optimized squeezing method yielded extracts with concentrations approximately 10 times higher than those obtained in conventional extraction methods. Yield comparison of various constituents, such as flavoring compounds, in e-cigarette aerosol extracts revealed similar extraction efficiencies between the squeezing and conventional methods. However, the extraction efficiency for constituents with high log Pow values, predominantly found in HTP aerosol extracts, was unacceptably low using the squeezing method. In addition, solvent-free centrifuging, another type of extraction method, exhibited unsatisfactory results for even e-cigarette aerosols compared with the conventional method. Our findings suggest that the solvent-free squeezing method is suitable for extracting aerosol collected mass from e-cigarette aerosol but not from HTP aerosol. We anticipate that the solvent-free squeezing method will contribute to a deeper understanding of toxicological differences between e-cigarettes and conventional combustible cigarettes.
Collapse
Affiliation(s)
- Hiroshi Ito
- Scientific Product Assessment Center, R&D group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan
| | - Atsushi Shigeto
- Scientific Product Assessment Center, R&D group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan
| | - Tsuneo Hashizume
- Scientific Product Assessment Center, R&D group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| |
Collapse
|
2
|
Reilly SM, Cheng T, Feng C, Walters MJ. Harmful and Potentially Harmful Constituents in E-Liquids and Aerosols from Electronic Nicotine Delivery Systems (ENDS). Chem Res Toxicol 2024. [PMID: 38924487 DOI: 10.1021/acs.chemrestox.4c00093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2024]
Abstract
In 2012, the U.S. Food & Drug Administration (FDA) published an established list of 93 harmful and potentially harmful constituents (HPHCs) targeting four tobacco product types (cigarettes, cigarette tobacco, roll-your-own tobacco, smokeless tobacco). In 2016, the FDA finalized the deeming rule to regulate electronic nicotine delivery systems (ENDS). However, knowledge gaps exist regarding whether certain HPHCs are present in ENDS e-liquids and aerosols. We identified and addressed these gaps by conducting literature searches and then experimentally quantifying HPHCs in the e-liquid and aerosol of 37 ENDS brands based on gaps in the literature. The literature searches identified 66 e-liquid HPHCs and 68 aerosol HPHCs that have limited to no information regarding the quantifiability of these constituents. A contracted ISO 17025 accredited laboratory performed the HPHC quantifications. The availability of validated analytical methods in the contracted laboratory determined the HPHCs included in the study scope (63/66 for e-liquids, 64/68 for aerosols). Combining the results from the quantifications and literature searches, 36 (39%) and 34 (37%) HPHCs were found quantifiable (≥limit of quantification [LOQ]) in ENDS e-liquids and aerosols, respectively, with 25 HPHCs being quantifiable in both matrices. Quantifiability results imply potential HPHC transfers between matrices, leaching from components, or formations from aerosol generation. The study results can inform the scientific basis for manufacturers and regulators regarding regulatory requirements for HPHC reporting. The HPHC quantities can also inform evaluations of the public health impact of ENDS and public communications regarding ENDS health risks.
Collapse
Affiliation(s)
- Samantha M Reilly
- Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, United States
| | - Tianrong Cheng
- Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, United States
| | - Charles Feng
- Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, United States
| | - Matthew J Walters
- Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, United States
| |
Collapse
|
3
|
Thorne D, McHugh D, Simms L, Lee KM, Fujimoto H, Moses S, Gaca M. Applying new approach methodologies to assess next-generation tobacco and nicotine products. FRONTIERS IN TOXICOLOGY 2024; 6:1376118. [PMID: 38938663 PMCID: PMC11208635 DOI: 10.3389/ftox.2024.1376118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Accepted: 04/30/2024] [Indexed: 06/29/2024] Open
Abstract
In vitro toxicology research has accelerated with the use of in silico, computational approaches and human in vitro tissue systems, facilitating major improvements evaluating the safety and health risks of novel consumer products. Innovation in molecular and cellular biology has shifted testing paradigms, with less reliance on low-throughput animal data and greater use of medium- and high-throughput in vitro cellular screening approaches. These new approach methodologies (NAMs) are being implemented in other industry sectors for chemical testing, screening candidate drugs and prototype consumer products, driven by the need for reliable, human-relevant approaches. Routine toxicological methods are largely unchanged since development over 50 years ago, using high-doses and often employing in vivo testing. Several disadvantages are encountered conducting or extrapolating data from animal studies due to differences in metabolism or exposure. The last decade saw considerable advancement in the development of in vitro tools and capabilities, and the challenges of the next decade will be integrating these platforms into applied product testing and acceptance by regulatory bodies. Governmental and validation agencies have launched and applied frameworks and "roadmaps" to support agile validation and acceptance of NAMs. Next-generation tobacco and nicotine products (NGPs) have the potential to offer reduced risks to smokers compared to cigarettes. These include heated tobacco products (HTPs) that heat but do not burn tobacco; vapor products also termed electronic nicotine delivery systems (ENDS), that heat an e-liquid to produce an inhalable aerosol; oral smokeless tobacco products (e.g., Swedish-style snus) and tobacco-free oral nicotine pouches. With the increased availability of NGPs and the requirement of scientific studies to support regulatory approval, NAMs approaches can supplement the assessment of NGPs. This review explores how NAMs can be applied to assess NGPs, highlighting key considerations, including the use of appropriate in vitro model systems, deploying screening approaches for hazard identification, and the importance of test article characterization. The importance and opportunity for fit-for-purpose testing and method standardization are discussed, highlighting the value of industry and cross-industry collaborations. Supporting the development of methods that are accepted by regulatory bodies could lead to the implementation of NAMs for tobacco and nicotine NGP testing.
Collapse
Affiliation(s)
- David Thorne
- BAT (Investments) Ltd., Southampton, Hampshire, United Kingdom
| | - Damian McHugh
- PMI R&D Philip Morris Products S. A., Neuchâtel, Switzerland
| | - Liam Simms
- Imperial Brands, Bristol, United Kingdom
| | - K. Monica Lee
- Altria Client Services LLC, Richmond, VA, United States
| | | | | | - Marianna Gaca
- BAT (Investments) Ltd., Southampton, Hampshire, United Kingdom
| |
Collapse
|
4
|
Mori A, Ito S, Sekine T. A revision of the multiple-path particle dosimetry model focusing on tobacco product aerosol dynamics. INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING 2024; 40:e3796. [PMID: 38185887 DOI: 10.1002/cnm.3796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 10/15/2023] [Accepted: 11/26/2023] [Indexed: 01/09/2024]
Abstract
To assess the health impact of inhaled aerosols, it is necessary to understand aerosol dynamics and the associated dosimetry in the human respiratory tract. Although several studies have measured or simulated the dosimetry of aerosol constituents, the respiratory tract focus areas have been limited. In particular, the aerosols generated from tobacco products are complex composites and simulating their dynamics in the respiratory tract is challenging. To assess the dosimetry of the aerosol constituents of tobacco products, we developed a revised version of the Multiple-Path Particle Dosimetry (MPPD) model, which employs (1) new geometry based on CT-scanned human respiratory tract data, (2) convective mixing in the oral cavity and deep lung, and (3) constituent partitioning between the tissue and air, and clearance. The sensitivity analysis was conducted using aerosols composed of four major constituents of electronic cigarette (EC) aerosols to investigate the parameters that have a significant impact on the results. In addition, the revised model was run with 4 and 10 constituents in ECs and conventional cigarettes (CCs), respectively. Sensitivity analysis revealed that the new modeling and the physicochemical properties of constituents had a considerable impact on the simulated aerosol concentration and dosimetry. The simulations could be carried out within 3 min even when 10 constituents of CC aerosols were analyzed simultaneously. The revised model based on MPPD is an efficient and easy-to-use tool for understanding the aerosol dynamics of CC and EC constituents and their effect on the human body.
Collapse
Affiliation(s)
- Akina Mori
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, Japan
| | - Shigeaki Ito
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, Japan
| | - Takashi Sekine
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, Japan
| |
Collapse
|
5
|
Kurachi T, Chuman S, Suzuki T, Kubota T, Ishikawa S. Effects of aerosols from heated tobacco products with flavors on the discoloration of bovine tooth enamel. Clin Exp Dent Res 2023; 9:1069-1077. [PMID: 37438937 PMCID: PMC10728517 DOI: 10.1002/cre2.764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 03/31/2023] [Accepted: 06/22/2023] [Indexed: 07/14/2023] Open
Abstract
OBJECTIVES This in vitro study assessed the potential of tooth discoloration by aerosols generated from three heated tobacco products (HTPs) with different specifications: in-direct heating tobacco system platform 1.0a (IT1.0a), in-direct heating tobacco system platform 2.0a (IT2.0a), and direct heating tobacco system platform 3.0a (DT3.0a). In addition, three flavor types (regular, menthol, and berry menthol) were selected for each HTP to characterize the effect of flavor types on tooth discoloration. MATERIAL AND METHODS Six bovine tooth samples were exposed directly to aerosols generated from one pack of each HTP: 350 puffs for IT1.0a, 325 puffs for IT2.0a, and 220 puffs for DT3.0a. Six bovine tooth samples were also exposed to air (350 puffs) and smoke generated from one pack of cigarettes (160 puffs) as negative and positive controls, respectively. The color of each tooth sample was measured before and after exposure. The overall color changes were assessed using overall color differences (ΔE) calculated according to the Commission International de I'Eclairage color system. A one-way analysis of variance followed by Tukey's post hoc test was used to compare ΔE among bovine tooth samples exposed to air, cigarette smoke, and aerosols generated from each HTP. RESULTS ΔE values for tooth samples exposed to air and aerosols generated from the three HTPs (IT1.0a, IT2.0a, and DT3.0a) were significantly lower than ΔE value for tooth samples exposed to cigarette smoke. ΔE values obtained with DT3.0a were significantly higher than those obtained with air-exposed control samples. However, ΔE values obtained with IT1.0a and IT2.0a were not significantly different from that obtained with air-exposed control samples. No HTPs showed significant differences in ΔE values among the three flavor types. CONCLUSIONS This study showed that HTP aerosols reduce tooth discoloration potential compared with cigarette smoke, regardless of flavor types, and the tooth discoloration potential of the product may depend on product specifications.
Collapse
Affiliation(s)
- Takeshi Kurachi
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc.YokohamaKanagawaJapan
| | - Shinnosuke Chuman
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc.YokohamaKanagawaJapan
| | - Takuya Suzuki
- Scientific and Regulatory Affairs, JT International SAGenevaSwitzerland
| | | | - Shinkichi Ishikawa
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc.YokohamaKanagawaJapan
| |
Collapse
|
6
|
Bishop E, Gaça M, Thorne D. Advances in whole aerosol approaches for in vitro e-cigarette testing. Drug Test Anal 2023; 15:1133-1144. [PMID: 36945752 DOI: 10.1002/dta.3471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 03/03/2023] [Accepted: 03/10/2023] [Indexed: 03/23/2023]
Abstract
Electronic-cigarette regulation and risk assessment is a prominent and developing field, as the popularity and prevalence of this product category increases. Over the last 10 years since their emergence, there have been many advances and adaptations to current in vitro testing techniques to better assess and predict absolute consumer risk. However, there are still requirements to create a cross-field harmonised approach to appropriate exposure and experimental design. With many assessments still being carried out using methods developed and optimised for cigarette smoke, there must first be an acknowledgement regarding the differences between cigarette smoke and tobacco-free e-cigarette aerosols before we can accurately assess these distinct products. Here, we discuss five published studies from within our own research to demonstrate how in vitro testing techniques have evolved to improve determination of risk by considering appropriate dosimetry and exposure for both e-cigarette and cigarette aerosols and how we can contextualise the data through human consumption and dose extrapolation, ultimately giving more relevance to in vitro data. Furthermore, we have demonstrated the evolution of techniques, which has allowed us to bridge between platforms, simplify exposure set-up, experimental design and demonstrate technology evolution within our products, thus fulfilling a responsible duty of care to consumers via an appropriate and robust in vitro product assessment.
Collapse
Affiliation(s)
- Emma Bishop
- British American Tobacco, R&D, Southampton, UK
| | | | | |
Collapse
|
7
|
Sato A, Ishigami A. Effects of heated tobacco product aerosol extracts on DNA methylation and gene transcription in lung epithelial cells. Toxicol Appl Pharmacol 2023; 475:116637. [PMID: 37499768 DOI: 10.1016/j.taap.2023.116637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Revised: 07/18/2023] [Accepted: 07/24/2023] [Indexed: 07/29/2023]
Abstract
AIMS Smoking causes DNA methylation (DNAm) alterations that lead to lung cancer development. Although the use of heated tobacco products (HTPs) has recently increased, their impact on health remains unclear. This study aimed to evaluate the effects of HTPs on DNAm and gene transcription in human lung epithelial cells in vitro. MAIN METHODS Human lung adenocarcinoma (A549) cells with type II alveolar epithelial characteristics were treated with aerosol extracts of two HTPs or a smoke extract of combustible reference cigarette (RC). Global 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) levels were quantified using dot blot analysis. Furthermore, reduced representation of bisulfite sequencing, DNA microarray, and quantitative PCR analyses were performed to determine CpG methylation and gene transcription changes induced by HTP and RC. KEY FINDINGS Global 5-mC and 5-hmC levels were decreased by the RC extract but not the HTP extracts. However, an HTP extract altered the CpG methylation pattern, and Gene Ontology enrichment analysis of the differentially methylated regions of the RC and HTP groups showed a similar pattern. The HTP extract affected gene expression, albeit to a lesser extent than the RC extract. In particular, the HTP extract markedly affected the mRNA expression and promoter methylation of cytochrome P450 family 1 subfamily A member 1 (CYP1A1), which is associated with carcinogenic risk. SIGNIFICANCE The study results suggest that HTPs as well as conventional combustible cigarettes can alter CpG methylation and gene transcription in lung epithelial cells.
Collapse
Affiliation(s)
- Ayami Sato
- Molecular Regulation of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo 173-0015, Japan
| | - Akihito Ishigami
- Molecular Regulation of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo 173-0015, Japan.
| |
Collapse
|
8
|
Zeng T, Liu Y, Jiang Y, Zhang L, Zhang Y, Zhao L, Jiang X, Zhang Q. Advanced Materials Design for Adsorption of Toxic Substances in Cigarette Smoke. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2023:e2301834. [PMID: 37211707 PMCID: PMC10401148 DOI: 10.1002/advs.202301834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 04/27/2023] [Indexed: 05/23/2023]
Abstract
Cigarettes, despite being economically important legal consumer products, are highly addictive and harmful, particularly to the respiratory system. Tobacco smoke is a complex mixture containing over 7000 chemical compounds, 86 of which are identified to have "sufficient evidence of carcinogenicity" in either animal or human tests. Thus, tobacco smoke poses a significant health risk to humans. This article focuses on materials that help reduce the levels of major carcinogens in cigarette smoke; these include nicotine, polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, hydrogen cyanide, carbon monoxide, and formaldehyde. Specifically, the research progress on adsorption effects and mechanisms of advanced materials such as cellulose, zeolite, activated carbon, graphene, and molecularly imprinted polymers are highlighted. The future trends and prospects in this field are also discussed. Notably, with advancements in supramolecular chemistry and materials engineering, the design of functionally oriented materials has become increasingly multidisciplinary. Certainly, several advanced materials can play a critical role in reducing the harmful effects of cigarette smoke. This review aims to serve as an insightful reference for the design of hybrid and functionally oriented advanced materials.
Collapse
Affiliation(s)
- Ting Zeng
- School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, 611731, China
- Research Center, Chengdu Medical College, Chengdu, 610500, China
| | - Yanxia Liu
- School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, 611731, China
| | - Yingfang Jiang
- School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, 611731, China
| | - Lan Zhang
- Univ Lyon, CNRS, INSA-Lyon, Université Claude Bernard Lyon 1, CETHIL UMR5008, Villeurbanne, F-69621, France
| | - Yagang Zhang
- School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, 611731, China
| | - Lin Zhao
- School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, 611731, China
| | - Xiaoli Jiang
- School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, 611731, China
| | - Qiang Zhang
- Department of Chemistry, Washington State University, Pullman, WA, 99164, USA
| |
Collapse
|
9
|
Dempsey R, Rodrigo G, Vonmoos F, Gunduz I, Belushkin M, Esposito M. Preliminary toxicological assessment of heated tobacco products: A review of the literature and proposed strategy. Toxicol Rep 2023; 10:195-205. [PMID: 36748021 PMCID: PMC9898577 DOI: 10.1016/j.toxrep.2023.01.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 12/20/2022] [Accepted: 01/18/2023] [Indexed: 01/21/2023] Open
Abstract
Heated tobacco products (HTP) have become increasingly common in many countries worldwide. The principle of heating tobacco, without combustion, to produce a nicotine-containing aerosol with remarkably reduced levels of other known toxins, compared to combusted tobacco cigarettes, is now well established. As these products are intended as alternatives to traditional combusted products, during the early stages of their development, it is important for manufacturers to ensure that the design of the product does not lead to any unintentionally increased or new risk for the consumer, compared to the traditional products that consumers seek to replace. There is limited guidance from tobacco product regulations concerning the requirements for performing such preliminary toxicological assessments. Here, we review the published literature on studies performed on HTPs in the pursuit of such data, outline a proposed approach that is consistent with regulatory requirements, and provide a logical approach to the preliminary toxicological assessment of HTPs.
Collapse
Affiliation(s)
- Ruth Dempsey
- RD Science Speaks Consultancy Sàrl, Le Mont sur Lausanne, Switzerland,Corresponding authors.
| | - Gregory Rodrigo
- PMI R&D, Philip Morris Products S.A., Rue des Usines 56, 2000 Neuchâtel, Switzerland,Corresponding authors.
| | - Florence Vonmoos
- PMI R&D, Philip Morris Products S.A., Rue des Usines 56, 2000 Neuchâtel, Switzerland
| | - Irfan Gunduz
- PMI R&D, Philip Morris Products S.A., Rue des Usines 56, 2000 Neuchâtel, Switzerland
| | - Maxim Belushkin
- PMI R&D, Philip Morris Products S.A., Rue des Usines 56, 2000 Neuchâtel, Switzerland
| | - Marco Esposito
- PMI R&D, Philip Morris Products S.A., Rue des Usines 56, 2000 Neuchâtel, Switzerland
| |
Collapse
|
10
|
Chemical and in vitro toxicological comparison of emissions from a heated tobacco product and the 1R6F reference cigarette. Toxicol Rep 2023; 10:281-292. [PMID: 36876026 PMCID: PMC9976195 DOI: 10.1016/j.toxrep.2023.02.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 02/06/2023] [Accepted: 02/14/2023] [Indexed: 02/17/2023] Open
Abstract
It has previously been found that, compared with cigarette smoke, the aerosols generated by heated tobacco products contain fewer and lower harmful and potentially harmful constituents (HPHCs) and elicit lower biological activity in in vitro models and lower smoking-related exposure biomarker levels in clinical studies. It is important to accumulate such scientific evidences for heated tobacco products with a novel heating system, because different heating system may affect the quantitative aspect of the amount of HPHCs and the qualitative aspect of the biological activity of the aerosol generated. Here, the chemical properties of, and toxicological responses to aerosols emitted by DT3.0a, a new heated tobacco product with a novel heating system, and cigarette smoke (CS) were compared, using chemical analyses, in vitro battery (standardized genotoxicity and cytotoxicity) assays, and mechanistic (ToxTracker and two-dimensional cell culture) assays. Regular- and menthol-flavored DT3.0a and standard 1R6F reference cigarettes were tested. Selected HPHC yields were lower in DT3.0a aerosol than 1R6F CS. The genotoxicity-related assays indicated that DT3.0a aerosol was not genotoxic, regardless of metabolic activation. The other biological assays indicated that less cytotoxicity induction and oxidative stress response were elicited by DT3.0a aerosol compared with 1R6F CS. Similar results were found for both regular and menthol DT3.0a. Like previous reports for heated tobacco products with other heating systems, the results of this study indicated that DT3.0a aerosols have chemical and biological properties less likely to be harmful than 1R6F CS.
Collapse
Key Words
- ACM, aerosol collected mass
- ARE, anti-oxidant responsive element
- AqE, aqueous extract
- BDL, below detection limit
- CMF-PBS, calcium- and magnesium-free phosphate buffered saline
- CS, cigarette smoke
- Cytotoxicity
- DT3.0a, Direct Heating Tobacco System Platform 3 generation 3 version a
- GFP, green fluorescent protein
- GVP, gas-vapor phase
- Genotoxicity
- HPHCs
- HPHCs, harmful and potentially harmful constituents
- HTP, heated tobacco product
- Heated tobacco product
- IC50, half maximal inhibitory concentration
- ISO, International Organization for Standardization
- In vitro
- LOD, limit of detection
- LOQ, limit of quantification
- MLA, mouse lymphoma assay
- MN, micronucleus
- MRTP, modified risk tobacco product
- NQ, not quantified
- NRU, neutral red uptake
- Oxidative stress
- ROS, reactive oxygen species
- THP, tobacco heating product
- THS, tobacco heating system
- TPM, total particulate matter
- mES, mouse embryonic stem
Collapse
|
11
|
Hattori N, Nakagawa T, Yoneda M, Hayashida H, Nakagawa K, Yamamoto K, Htun MW, Shibata Y, Koji T, Ito T. Compounds in cigarette smoke induce EGR1 expression via the AHR, resulting in apoptosis and COPD. J Biochem 2022; 172:365-376. [PMID: 36200927 DOI: 10.1093/jb/mvac077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 09/13/2022] [Indexed: 12/13/2022] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide, and pulmonary epithelial cell apoptosis is regarded as one of the most important factors in its pathogenesis. Here, we examined the molecular mechanisms of apoptosis caused by cigarette smoke (CS). In the normal bronchial epithelium cell line BEAS-2B, a CS extract markedly induced apoptosis together with transient early growth response 1 (EGR1) protein expression, which is activated over time via the aryl hydrocarbon receptor (AHR). The CS extract-induced apoptosis decreased cell count of BEAS-2B cells and was significantly reversed by knockdown of either EGR1 or AHR. In vivo, the CS extract caused alveolar wall destruction, mimicking COPD, 1 week after intrathoracic injection. Bronchoalveolar lavage fluid (BALF) from the CS extract-treated mice contained massive numbers of apoptotic epithelial cells. Furthermore, it was found that aminoanthracene induced EGR1 expression and cell apoptosis. By contrast, the AHR antagonist stemregenin 1 (SR1) restored apoptosis upon CS treatment. These results suggest that aryl hydrocarbons, such as aminoanthracene, induce EGR1 expression via the AHR, resulting in cell apoptosis and that this can be prevented by administration of an antagonist of AHR.
Collapse
Affiliation(s)
- Naoko Hattori
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan.,Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
| | - Takeya Nakagawa
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Mitsuhiro Yoneda
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Hiromi Hayashida
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Kaori Nakagawa
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Kazuo Yamamoto
- Biomedical Research Support Center, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Myo Win Htun
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Histology and Cell Biology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Yasuaki Shibata
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
| | - Takehiko Koji
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Histology and Cell Biology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| | - Takashi Ito
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.,Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan
| |
Collapse
|
12
|
Kęska A, Janicka A, Zawiślak M, Molska J, Włostowski R, Włóka A, Świeściak J, Ostrowski K. Assessment of the Actual Toxicity of Engine Exhaust Gas Emissions from Euro 3 and Euro 6 Compliant Vehicles with the BAT-CELL Method Using In Vitro Tests. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:14138. [PMID: 36361013 PMCID: PMC9654593 DOI: 10.3390/ijerph192114138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 10/21/2022] [Accepted: 10/26/2022] [Indexed: 06/16/2023]
Abstract
Legal restrictions on vehicle engine exhaust gas emission control do not always go hand in hand with an actual reduction in the emissions of toxins into the atmosphere. Moreover, the methods currently used to measure exhaust gas emissions do not give unambiguous results on the impact of the tested gases on living organisms. The method used to assess the actual toxicity of gases, BAT-CELL Bio-Ambient-Tests using in vitro tests, takes into account synergistic interactions of individual components of a mixture of gases without the need to know its qualitative and quantitative composition and allows for determination of the actual toxicity of the gas composition. Using the BAT-CELL method, exhaust gases from passenger vehicles equipped with spark-ignition engines complying with the Euro 3 and Euro 6 emission standards were tested. The results of toxicological tests were correlated with the results of chromatographic analysis. It was shown that diverse qualitative composition of the mixture of hydrocarbons determining the exhaust gases toxicity may decrease the percentage value of cell survival. Additionally, it was proven that the average survival of cells after exposure to exhaust gases from tested vehicles meeting the more restrictive Euro 6 standard was lower than for vehicles meeting the Euro 3 standard thus indicating the higher toxicity of exhaust gases from newer vehicles.
Collapse
|
13
|
Yuki D, Kikuchi A, Suzuki T, Sakaguchi C, Huangfu D, Nagata Y, Kakehi A. Assessment of the exposure to selected smoke constituents in adult smokers using in-market heated tobacco products: a randomized, controlled study. Sci Rep 2022; 12:18167. [PMID: 36307514 PMCID: PMC9616951 DOI: 10.1038/s41598-022-22997-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 10/21/2022] [Indexed: 12/31/2022] Open
Abstract
The objectives of this clinical study were to demonstrate a reduction in exposure to selected harmful and potentially harmful constituents (HPHCs) in Japanese healthy adult smokers who switched to four in-market heated tobacco products. Eighty-nine smokers were randomly assigned for five days to one of six study groups: four groups who switched to one of the commercially available heated tobacco products; a group who continued to smoke their own brand of combustible cigarettes (CC); or a group who stopped smoking (SS). Fifteen biomarkers of exposure (BoE) to 14 HPHCs and pyrene were measured at baseline, Day 3 and Day 5 in 24 h urine and breath, under clinical confinement. Product consumption, nicotine uptake and subjective effects were also measured before and after product switching. On Day 5, significant reductions in most BoE relative to the CC group were observed after switching to heated tobacco products. No changes in BoE were observed between baseline and Day 5 in the CC group. Significantly, the magnitude of the reduction in exposure to most of the selected HPHCs observed in the heated tobacco product groups was close to that observed in the SS group.
Collapse
Affiliation(s)
- Dai Yuki
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| | - Akira Kikuchi
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| | - Takuya Suzuki
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| | - Chikako Sakaguchi
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| | - Danting Huangfu
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| | - Yasufumi Nagata
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| | - Aoi Kakehi
- grid.417743.20000 0004 0493 3502Scientific and Regulatory Affairs, Japan Tobacco Inc., 4-1-1 Toranomon Minato-ku, Tokyo, 105-6927 Japan
| |
Collapse
|
14
|
The Impact of Tobacco Cigarettes, Vaping Products and Tobacco Heating Products on Oxidative Stress. Antioxidants (Basel) 2022; 11:antiox11091829. [PMID: 36139904 PMCID: PMC9495690 DOI: 10.3390/antiox11091829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 09/06/2022] [Accepted: 09/08/2022] [Indexed: 12/02/2022] Open
Abstract
Cells constantly produce oxidizing species because of their metabolic activity, which is counteracted by the continuous production of antioxidant species to maintain the homeostasis of the redox balance. A deviation from the metabolic steady state leads to a condition of oxidative stress. The source of oxidative species can be endogenous or exogenous. A major exogenous source of these species is tobacco smoking. Oxidative damage can be induced in cells by chemical species contained in smoke through the generation of pro-inflammatory compounds and the modulation of intracellular pro-inflammatory pathways, resulting in a pathological condition. Cessation of smoking reduces the morbidity and mortality associated with cigarette use. Next-generation products (NGPs), as alternatives to combustible cigarettes, such as electronic cigarettes (e-cig) and tobacco heating products (THPs), have been proposed as a harm reduction strategy to reduce the deleterious impacts of cigarette smoking. In this review, we examine the impact of tobacco smoke and MRPs on oxidative stress in different pathologies, including respiratory and cardiovascular diseases and tumors. The impact of tobacco cigarette smoke on oxidative stress signaling in human health is well established, whereas the safety profile of MRPs seems to be higher than tobacco cigarettes, but further, well-conceived, studies are needed to better understand the oxidative effects of these products with long-term exposure.
Collapse
|
15
|
Crooks I, Hollings M, Leverette R, Jordan K, Breheny D, Moore MM, Thorne D. A comparison of cigarette smoke test matrices and their responsiveness in the mouse lymphoma assay: A case study. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2022; 879-880:503502. [PMID: 35914858 DOI: 10.1016/j.mrgentox.2022.503502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 05/22/2022] [Accepted: 05/24/2022] [Indexed: 06/15/2023]
Abstract
No cigarette smoke test matrix is without limitation, due to the complexity of the starting aerosol and phase to phase dynamics. It is impossible to capture all chemicals at the same level of efficiency, therefore, any test matrix will inadvertently or by design fractionate the test aerosol. This case study examines how four different test matrices derived from cigarette smoke can be directly compared. The test matrices assessed were as follows, total particulate matter (TPM), gas vapour phase (GVP), a combination of TPM + GVP and whole aerosol (WA). Here we use an example assay, the mouse lymphoma assay (MLA) to demonstrate that data generated across four cigarette smoke test matrices can be compared. The results show that all test matrices were able to induce positive mutational events, but with clear differences in the biological activity (both potency and toxicity) between them. TPM was deemed the most potent test article and by extension, the particulate phase is interpreted as the main driver of genotoxic induced responses in the MLA. However, the results highlight that the vapour phase is also active. MLA appeared responsive to WA, with potentially lower potency, compared to TPM approaches. However, this observation is caveated in that the WA approaches used for comparison were made on a newly developed experimental method using dose calculations. The TPM + GVP matrix had comparable activity to TPM alone, but interestingly induced a greater number of mutational events at comparable relative total growth (RTG) and TPM-equivalent doses when compared to other test matrices. In conclusion, this case study highlights the importance of understanding test matrices in response to the biological assay being assessed and we note that not all test matrices are equal.
Collapse
Affiliation(s)
- Ian Crooks
- B.A.T. (Investments) Limited, Regents Park Road, Millbrook, Southampton SO15 8TL, UK
| | - Michael Hollings
- Labcorp Early Development Laboratories Ltd., Harrogate, North Yorkshire HG3 1PY, UK
| | - Robert Leverette
- Reynolds American Inc, 950 Reynolds Blvd., Winston-Salem, NC 27105, USA
| | - Kristen Jordan
- Reynolds American Inc, 950 Reynolds Blvd., Winston-Salem, NC 27105, USA
| | - Damien Breheny
- B.A.T. (Investments) Limited, Regents Park Road, Millbrook, Southampton SO15 8TL, UK
| | | | - David Thorne
- B.A.T. (Investments) Limited, Regents Park Road, Millbrook, Southampton SO15 8TL, UK.
| |
Collapse
|
16
|
Bishop E, Terry A, East N, Breheny D, Gaca M, Thorne D. A 3D in vitro comparison of two undiluted e-cigarette aerosol generating systems. Toxicol Lett 2022; 358:69-79. [PMID: 35032609 DOI: 10.1016/j.toxlet.2022.01.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 11/19/2021] [Accepted: 01/11/2022] [Indexed: 10/19/2022]
Abstract
In vitro studies play an important role in supporting the toxicological assessment of e-cigarettes, with many current methods reliant on sophisticated in vitro exposure systems designed for conventional cigarette testing. In this study, we have compared two distinct systems; the modified Vitrocell VC10 and Borgwaldt LM4E designed to deliver undiluted e-cigarette aerosol. We assessed the cytotoxicity response of 3D reconstituted lung tissue (MucilAir) exposed to undiluted aerosol from ePen3 (closed modular e-cigarette) using these two exposure systems. As the induced cytotoxicity profiles were comparable, we then compared these responses against historical eBox (open modular e-cigarette) and 3R4F reference cigarette data to show evolution of product technology. This latter approach was deemed possible by monitoring intrinsic donor-to-donor control variability over a three-year period, bridging between exposure systems and observed biological responses. Despite the differences in the technology, on a puff-by-puff basis these machines gave remarkably similar cytotoxicity profiles for ePen3, as determined by MTT, and consistency of pre-cytotoxicity markers: transepithelial electrical resistance (TEER), cilia beat frequency and cilia active area. When responses are compared as a function of exposed nicotine concentration, we see differences due to the dynamics of the exposure systems. The parity of responses between the systems in generated undiluted aerosol has allowed us to compare back to previously published eBox data, irrespective of aerosol generating system and MucilAir donor, showing how evolution from open systems to podmod e-cigarette design can make a step change in the cytotoxicity profile of the product.
Collapse
Affiliation(s)
- E Bishop
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK.
| | - A Terry
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - N East
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - D Breheny
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - M Gaca
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - D Thorne
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| |
Collapse
|
17
|
Yamamoto H, Shibuya K, Fukushima T, Hashizume T. Effects of antioxidant capacity on micronucleus induction by cigarette smoke in mammalian cells. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2022; 873:503427. [PMID: 35094812 DOI: 10.1016/j.mrgentox.2021.503427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 11/10/2021] [Accepted: 11/11/2021] [Indexed: 06/14/2023]
Abstract
We have compared micronucleus (MN) induction by cigarette smoke in the L5178Y, TK6, and CHL/IU cell lines. The test sample was total particulate matter of 3R4F reference cigarette smoke, suspended in DMSO. After 3-h treatment, with or without a rat liver S9 metabolic activation system, followed by 24-h recovery, dose-dependent MN increases were seen in all cell lines. However, CHL/IU and TK6 cells were more resistant than L5178Y cells (comparison by Benchmark Doses with PROAST software). 3R4F smoke generates reactive oxygen species (ROS). Therefore, we explored the relationship between the sensitivities to 3R4F smoke and the antioxidant capacities of the cell lines. While the total antioxidant capacities were not significantly different among the cell lines, cellular glutathione (GSH) was higher in CHL/IU cells than in L5178Y cells. Pretreatment of CHL/IU cells with a GSH precursor, N-acetylcysteine (NAC), reduced the genotoxicity/cytotoxicity of 3R4F, whereas an inhibitor of GSH biosynthesis, buthionine sulfoximine (BSO), enhanced it. The effects of NAC and BSO were also seen after treatment with allyl isothiocyanate, a ROS-generating chemical, but not with mitomycin C, a ROS-independent genotoxicant. Pretreatment with NAC increased cellular thiol levels. From the present results, the genotoxicity and cytotoxicity of cigarette smoke differs among these cell lines in a manner that may be related to their antioxidant thiol levels.
Collapse
Affiliation(s)
- Haruna Yamamoto
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Kaori Shibuya
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Toshiro Fukushima
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Tsuneo Hashizume
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| |
Collapse
|
18
|
Horinouchi T, Miwa S. Comparison of cytotoxicity of cigarette smoke extract derived from heat-not-burn and combustion cigarettes in human vascular endothelial cells. J Pharmacol Sci 2021; 147:223-233. [PMID: 34507631 DOI: 10.1016/j.jphs.2021.07.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 07/06/2021] [Accepted: 07/20/2021] [Indexed: 11/30/2022] Open
Abstract
The present study compared the properties of mainstream smoke generated from heat-not-burn (HNB) cigarettes and a combustion cigarette (hi-lite™ brand). Three types of cigarette heating devices were used to generate cigarette smoke at different heating temperatures [Ploom S™ (200 °C), glo™ (240 °C), and IQOS™ (300-350 °C)]. Mainstream smoke was generated using the following puffing regimen: volume, 55 mL; duration, 3 s; and interval, 30 s. The rank order of particulate phase (nicotine and tar) amounts trapped on a Cambridge filter was Ploom S < glo < IQOS < hi-lite. Heated cigarette-derived smoke extract (hCSE) from the devices except for Ploom S, and burned CSE (bCSE) decreased mitochondrial metabolic activity (glo < IQOS < hi-lite) in human vascular endothelial cells. Furthermore, the cytotoxicity was reduced by removing the particulate phase from the mainstream smoke. Endothelial nitric oxide synthase activity was reduced by nicotine- and tar-free CSE of IQOS and hi-lite (IQOS < hi-lite), but not Ploom S and glo. These inhibitory effects were diminished by removing the carbonyl compounds from the mainstream smoke. These results indicated that the cytotoxicity of hCSE was lower than that of bCSE in vascular endothelial cells.
Collapse
Affiliation(s)
- Takahiro Horinouchi
- Department of Cellular Pharmacology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
| | - Soichi Miwa
- Toyooka General Hospital, 1094 Tobera, Toyooka, Hyogo, 668-8501, Japan
| |
Collapse
|
19
|
Sakaguchi C, Nagata Y, Kikuchi A, Takeshige Y, Minami N. Differences in Levels of Biomarkers of Potential Harm Among Users of a Heat-Not-Burn Tobacco Product, Cigarette Smokers, and Never-Smokers in Japan: A Post-Marketing Observational Study. Nicotine Tob Res 2021; 23:1143-1152. [PMID: 33502518 PMCID: PMC8274485 DOI: 10.1093/ntr/ntab014] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 01/19/2021] [Indexed: 12/14/2022]
Abstract
Introduction Cigarette smoking is associated with the risk of certain diseases, but
non-combustible products may lower these risks. The potential long-term
health effects of the next-generation non-combustible products
(heat-not-burn tobacco products (HNBP) or electronic vapor products) have
not been thoroughly studied. The present study aimed to investigate the
impact of biomarkers of potential harm (BoPH) of one of HNBP (a novel vapor
product: NTV (novel tobacco vapor)), under the conditions of actual use. Aims and Methods This study was an observational, cross-sectional, three-group, multi-center
study. Exclusive NTV users (NTV, n = 259), conventional
cigarette smokers (CC, n = 100) and never-smokers (NS,
n = 100) were enrolled. Biomarkers of tobacco smoke
exposure (cotinine and total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
(NNAL)) and BoPH including parameters of physical pulmonary functions
relevant to smoking-related diseases were examined, and subjects answered a
questionnaire on cough-related symptoms (J-LCQ) and health-related quality
of life (SF-36v2®). Results Levels of cotinine, total NNAL and BoPH (high-density lipoprotein
(HDL)-cholesterol, triglyceride, sICAM-1, WBC count, 11-DHTXB2, 2,3-d-TXB2,
8-epi-PGF2α, forced expiratory volume in 1 second (FEV1), % predicted
value of FEV1 (%FEV1) and maximum midexpiratory flow (FEF25-75))
were significantly different in the NTV group as compared to levels in CC
group (p < .05). Significantly higher levels of
cotinine, total NNAL, and 2,3-d-TXB2, and lower levels of FEV1 and %FEV1,
were observed among NTV users compared to the NS group. Conclusion In a post-marketing study under actual use conditions, BoPH associated with
smoking-related disease examined in exclusive NTV users were found to be
favorably different from those of CC smokers, a finding attributable to a
reduction in exposure to harmful substances of tobacco smoke. Implications Cigarette smoking is associated with an increased risk of pulmonary diseases
like COPD, cardiovascular diseases, and certain cancers. There is a growing
body of evidence that HNBP reduces the exposure associated with smoking and
that there is a favorable change in BoPH. However, long-term effects
regarding the relative health risks to HNBP users compared to CC smokers
have not been examined. This study provides post-marketing data under actual
use conditions of the effects on biomarkers of potential harm in NTV, one of
HNBP, exclusive users compared to CC smokers and never-smokers. The evidence
suggests that exclusive NTV users have favorable levels of BoPH compared to
CC smokers, and that is result from a sustained reduction in exposure to
harmful substances of tobacco smoke.
Collapse
Affiliation(s)
| | - Yasufumi Nagata
- Scientific and Regulatory Affairs, Japan Tobacco Inc., Tokyo, Japan
| | - Akira Kikuchi
- Scientific and Regulatory Affairs, Japan Tobacco Inc., Tokyo, Japan
| | - Yuki Takeshige
- Scientific and Regulatory Affairs, Japan Tobacco Inc., Tokyo, Japan
| | - Naoki Minami
- Scientific and Regulatory Affairs, Japan Tobacco Inc., Tokyo, Japan
| |
Collapse
|
20
|
Hattori N, Nakagawa T, Yoneda M, Nakagawa K, Hayashida H, Ito T. Cigarette smoke, but not novel tobacco vapor products, causes epigenetic disruption and cell apoptosis. Biochem Biophys Rep 2020; 24:100865. [PMID: 33294641 PMCID: PMC7691555 DOI: 10.1016/j.bbrep.2020.100865] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Accepted: 11/15/2020] [Indexed: 11/18/2022] Open
Abstract
Heat-Not-Burn (HNB) products, generating vapor without combusting tobacco leaves, have been developed with the expectation that the number and quantity of chemicals in the vapor of these products would be reduced compared with the smoke from conventional combustible cigarettes. However, whether the lower chemical levels correlate with lower toxicity remains to be determined. Here we examined differences in the biological effects of conventional cigarette smoke (CS) and two HNB products, Ploom TECH and Ploom TECH+, using the cultured cancer cell line A549 and the normal bronchial epithelium cell line BEAS-2B. The conventional CS 3R4F extract (0.5%) markedly decreased cell proliferation of both A549 and BEAS-2B cells; however, 0.5% extracts of these commercially available HNB products did not affect cell growth. To determine the cause of decreased cell proliferation, a TUNEL assay was performed, and the results indicated that apoptosis had occurred in both A549 and BEAS-2B cells at 24 h after exposure to 3R4F. To further explore the effect of CS on epigenetics, we performed western blotting to detect histone H2A phosphorylation, which is known to affect transcriptional regulation. Only the 3R4F extract decreased histone H2A phosphorylation in both A549 and BEAS-2B cells. Next, we examined alterations in gene expression after treatment of A549 cells with Ploom TECH, Ploom TECH+, or 3R4F extracts. It was found that 339, 107, and 103 genes were upregulated more than 2 fold in A549 cells treated with 3R4F, Ploom TECH, or Ploom TECH + extracts, respectively. Among the 339 genes that were upregulated in response to 3R4F, we focused on EGR1, FOS, and FOSB, since they were upregulated more than 100 fold, which was confirmed using RT-qPCR. These results suggest that CS, but not HNB products, cause epigenetic disruption and cell apoptosis, possibly by elevating transcription of genes such as EGR1.
Collapse
Affiliation(s)
- Naoko Hattori
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki, Japan
| | - Takeya Nakagawa
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki, Japan
| | - Mitsuhiro Yoneda
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki, Japan
| | - Kaori Nakagawa
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki, Japan
| | - Hiromi Hayashida
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki, Japan
| | - Takashi Ito
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- Department of Biochemistry, Nagasaki University School of Medicine, Nagasaki, Japan
| |
Collapse
|
21
|
Hirn C, Kanemaru Y, Stedeford T, Paschke T, Baskerville-Abraham I. Comparative and cumulative quantitative risk assessments on a novel heated tobacco product versus the 3R4F reference cigarette. Toxicol Rep 2020; 7:1502-1513. [PMID: 33209587 PMCID: PMC7658373 DOI: 10.1016/j.toxrep.2020.10.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 10/09/2020] [Accepted: 10/23/2020] [Indexed: 12/16/2022] Open
Abstract
Novel tobacco products that heat rather than burn tobacco (heated tobacco products or HTPs) have been shown to produce lower levels of harmful and potentially harmful constituents than conventional combusted cigarettes. The present study uses a quantitative risk assessment approach to compare non-cancer and cancer risk estimates for emissions generated by an HTP with smoke from a reference cigarette (3R4F). Fifty-four analytes were evaluated from the HTP aerosol and the 3R4F cigarette smoke. Emissions were generated using the ISO and the Health Canada Intense smoking regimes. The measured values were extrapolated to define a conservative exposure assumption for per day use and lifetime use based on an estimated maximum usage level of 400 puffs per day i.e., approximately 8 HTP tobacco capsules or 40 combustible cigarettes. Non-cancer and cancer risk estimates were calculated using these exposure assumptions for individual and per health outcome domains based on toxicological reference values derived by regulatory and/or public health agencies. The results of this assessment showed a reduction of non-cancer and cancer risk estimates by more than 90 % for the HTP versus the 3R4F cigarette, regardless of the smoking regime.
Collapse
Affiliation(s)
| | | | | | - Thilo Paschke
- Scientific and Regulatory Affairs, JT International SA, Geneva, Switzerland
| | | |
Collapse
|
22
|
Smart DJ, Phillips G. Collecting e-cigarette aerosols for in vitro applications: A survey of the biomedical literature and opportunities to increase the value of submerged cell culture-based assessments. J Appl Toxicol 2020; 41:161-174. [PMID: 33015847 PMCID: PMC7756347 DOI: 10.1002/jat.4064] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 08/11/2020] [Accepted: 08/18/2020] [Indexed: 12/11/2022]
Abstract
Electronic nicotine delivery systems (ENDS) are being developed as potentially reduced‐risk alternatives to the continued use of combustible tobacco products. Because of the widespread uptake of ENDS—in particular, e‐cigarettes—the biological effects, including the toxic potential, of their aerosols are under investigation. Preclinically, collection of such aerosols is a prerequisite for testing in submerged cell culture‐based in vitro assays; however, despite the growth in this research area, there is no apparent standardized collection method for this application. To this end, through an Institute for in vitro Sciences, Inc. workshop initiative, we surveyed the biomedical literature catalogued in PubMed® to map the types of methods hitherto used and reported publicly. From the 47 relevant publications retrieved, we identified seven distinct collection methods. Bubble‐through (with aqueous solvents) and Cambridge filter pad (CFP) (with polar solvents) collection were the most frequently cited methods (57% and 18%, respectively), while the five others (CFP + bubble‐through; condensation; cotton filters; settle‐upon; settle‐upon + dry) were cited less often (2–10%). Critically, the collected aerosol fractions were generally found to be only minimally characterized chemically, if at all. Furthermore, there was large heterogeneity among other experimental parameters (e.g., vaping regimen). Consequently, we recommend that more comprehensive research be conducted to identify the method(s) that produce the fraction(s) most representative of the native aerosol. We also endorse standardization of the aerosol generation process. These should be regarded as opportunities for increasing the value of in vitro assessments in relation to predicting effects on human health. Collection of e‐cigarette aerosols is a prerequisite to enable testing in submerged culture‐based in vitro assays; however, there is no standardized method for this. Thus, we surveyed the biomedical literature to map the types of published methods. Bubble‐through and Cambridge filter pad methods were most common, although there was heterogeneity among other parameters, and moreover, the resulting fractions were only minimally characterized. Comprehensive research is required to identify the method(s) that produce the fraction(s) most representative of the native aerosol.
Collapse
Affiliation(s)
- Daniel J Smart
- PMI R&D, Philip Morris Products SA, Neuchâtel, Switzerland
| | | |
Collapse
|
23
|
Smith LC, Kallupi M, Tieu L, Shankar K, Jaquish A, Barr J, Su Y, Velarde N, Sedighim S, Carrette LLG, Klodnicki M, Sun X, de Guglielmo G, George O. Validation of a nicotine vapor self-administration model in rats with relevance to electronic cigarette use. Neuropsychopharmacology 2020; 45:1909-1919. [PMID: 32544927 PMCID: PMC7608444 DOI: 10.1038/s41386-020-0734-8] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 05/21/2020] [Accepted: 06/01/2020] [Indexed: 12/13/2022]
Abstract
The debate about electronic cigarettes is dividing healthcare professionals, policymakers, manufacturers, and communities. A key limitation in our understanding of the cause and consequences of vaping is the lack of animal models of nicotine vapor self-administration. Here, we developed a novel model of voluntary electronic cigarette use in rats using operant behavior. We found that rats voluntarily exposed themselves to nicotine vapor to the point of reaching blood nicotine levels that are similar to humans. The level of responding on the active (nicotine) lever was similar to the inactive (air) lever and lower than the active lever that was associated with vehicle (polypropylene glycol/glycerol) vapor, suggesting low positive reinforcing effects and low nicotine vapor discrimination. Lever pressing behavior with nicotine vapor was pharmacologically prevented by the α4β2 nicotinic acetylcholine receptor partial agonist and α7 receptor full agonist varenicline in rats that self-administered nicotine but not vehicle vapor. Moreover, 3 weeks of daily (1 h) nicotine vapor self-administration produced addiction-like behaviors, including somatic signs of withdrawal, allodynia, anxiety-like behavior, and relapse-like behavior after 3 weeks of abstinence. Finally, 3 weeks of daily (1 h) nicotine vapor self-administration produced cardiopulmonary abnormalities and changes in α4, α3, and β2 nicotinic acetylcholine receptor subunit mRNA levels in the nucleus accumbens and medial prefrontal cortex. These findings validate a novel animal model of nicotine vapor self-administration in rodents with relevance to electronic cigarette use in humans and highlight the potential addictive properties and harmful effects of chronic nicotine vapor self-administration.
Collapse
Affiliation(s)
- Lauren C. Smith
- grid.214007.00000000122199231Department of Neuroscience, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA USA ,Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | - Marsida Kallupi
- Department of Neuroscience, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA, USA. .,Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA, USA.
| | - Lani Tieu
- Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | - Kokila Shankar
- grid.214007.00000000122199231Department of Neuroscience, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA USA ,Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | - Abigail Jaquish
- grid.266102.10000 0001 2297 6811Department of Pediatrics, University of California, La Jolla, CA USA
| | - Jamie Barr
- grid.266102.10000 0001 2297 6811Department of Pediatrics, University of California, La Jolla, CA USA
| | - Yujuan Su
- grid.266102.10000 0001 2297 6811Department of Pediatrics, University of California, La Jolla, CA USA
| | - Nathan Velarde
- Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | - Sharona Sedighim
- Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | - Lieselot L. G. Carrette
- grid.214007.00000000122199231Department of Neuroscience, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA USA ,Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | | | - Xin Sun
- grid.266102.10000 0001 2297 6811Department of Pediatrics, University of California, La Jolla, CA USA
| | - Giordano de Guglielmo
- grid.214007.00000000122199231Department of Neuroscience, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA USA ,Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA USA
| | - Olivier George
- Department of Neuroscience, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA, USA. .,Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA, USA.
| |
Collapse
|
24
|
Breheny D, Thorne D, Baxter A, Bozhilova S, Jaunky T, Santopietro S, Taylor M, Terry A, Gaça M. The in vitro assessment of a novel vaping technology. Toxicol Rep 2020; 7:1145-1156. [PMID: 32983902 PMCID: PMC7494588 DOI: 10.1016/j.toxrep.2020.08.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 07/26/2020] [Accepted: 08/18/2020] [Indexed: 11/17/2022] Open
Abstract
We have developed a novel vaping product (NVP) IS1.0(TT), which utilises a stainless-steel mesh to transfer and vaporise the e-liquid, mitigating some of the potential sources of toxicants that can be generated using the more traditional 'wick and coil' approach. The emissions from IS1.0(TT) have previously been found to have lower levels of toxicants overall when directly compared with a commercial wick and coil e-cig. This current study assessed the toxicological responses to aerosols from this NVP. Responses induced by IS1.0(TT)were compared to those from a 3R4F reference cigarette, using in vitro test methods which included regulatory genetic toxicological assays as well as some more contemporary screening approaches. The experimental conditions were designed to facilitate the testing of aerosol from this vaping product at doses that in most cases greatly exceeded those of the 3R4F comparator showed little to no toxicological responses and demonstrated significantly reduced effects in these in vitro assays when compared to 3R4F. Furthermore, the extreme doses tested in the present study indicate that the toxicant profile of this NVP translates to lower biological activity in vitro, and suggests that the absolute risk hazard level associated with electronic cigarettes can be reduced through continuous improvement as the technology evolves.
Collapse
Key Words
- ACM, aerosol collected mass
- ALI, air-liquid interface
- ANOVA, analysis of variance
- ARE, antioxidant response element
- Aerosol
- AqE, aerosol aqueous extract
- AqE, aqueous aerosol extracts
- CRM81, CORESTA recommended method number 81
- Cigarette
- DCF, 2′,7′ dichlorodihydrofluorescein
- DMSO, dimethyl sulfoxide
- DSB, double-strand break
- Electronic cigarette
- FDA, US Food and Drug Administration
- GEF, global evaluation factor
- GSH, glutathione (reduced form)
- HCI, Health Canada Intense
- HUVEC, human umbilical vein endothelial cell
- ISO, International Organisation for Standardisation
- IVMn, in vitro micronucleus
- In vitro
- MF, mutant frequency
- MLA, mouse lymphoma assay
- NASEM, US National Academy of Sciences, Engineering and Medicine
- NHBE, normal human bronchial epithelial
- NRU, neutral red uptake
- NVP, new vapour product
- RWD, relative wound density
- S9, post-mitochondrial supernatant
- TPA, 12-O-tetradecanoylphorbol-13-acetate
- TPM, total particulate matter
- TobReg, WHO Study Group on Tobacco Product Regulation
- WA, whole aerosol
Collapse
|
25
|
Thorne D, Whitwell J, Clements J, Walker P, Breheny D, Gaca M. The genotoxicological assessment of a tobacco heating product relative to cigarette smoke using the in vitro micronucleus assay. Toxicol Rep 2020; 7:1010-1019. [PMID: 32874925 PMCID: PMC7451629 DOI: 10.1016/j.toxrep.2020.08.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 08/03/2020] [Accepted: 08/10/2020] [Indexed: 01/02/2023] Open
Abstract
In vitro studies have supported the toxicological evaluation of chemicals and complex mixtures including cigarette smoke and novel tobacco and nicotine products which include tobacco heating products (THP). This new environment requires faster testing, higher throughput and appropriate in vitro studies, to support product innovation and development. In this study, total particulate matter (TPM) from a commercially available THP and a reference cigarette (3R4F) were assessed up to 500 μg/mL using two in vitro micronucleus techniques. V79 and TK6 cells were assessed using conventional OECD 487 manual scoring techniques, whereas, CHO cells were assessed using contemporary, automated high content screening approaches (Cellomics ArrayScan® VTI). V79 cells gave the most consistent response with all three treatment conditions producing a clear positive genotoxic response. Human TK6 cells only produced dose-dependent response, indicative of a weak-positive response. CHO cells demonstrated a positive response with TPM using long (24 h) -S9 conditions. All three cell lines equally demonstrated a negative response with THP TPM up to 500 μg/mL. In conclusion, THP TPM did not increase micronuclei formation above control levels even at doses far exceeding that tested with reference cigarette smoke, in most cases up to 10x the dose delivered compared to that of cigarette smoke. This study supports the growing belief that THPs are less risky than conventional cigarettes and that 21st century screening techniques can be employed to support product design and decision making, as a potential 1st screen prior to more traditional assessments.
Collapse
Key Words
- 3R4F, Research reference cigarette
- CHO
- CRM, 81 CORESTA recommended method 81
- DMSO, dimethyl sulphoxide
- E-cigarette, electronic cigarette
- HCI, Health Canada Intense smoking regimen
- HCIm, Health Canada Intense modified smoking regimen
- High content screening
- ISO, International Standards Organisation
- IVMN
- IVMN, in vitro micronucleus assay
- In vitro
- NGP, Next generation products
- S9, mammalian liver post-mitochondrial fraction
- THP, tobacco heating product
- TK6
- TPM, total particulate matter
- Tobacco heating product
- V79
Collapse
Affiliation(s)
- David Thorne
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - James Whitwell
- Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
| | - Julie Clements
- Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
| | - Paul Walker
- Cyprotex Discovery, Alderley Park, Alderley, Cheshire, SK10 4TG, UK
| | - Damien Breheny
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - Marianna Gaca
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| |
Collapse
|
26
|
Wieczorek R, Phillips G, Czekala L, Trelles Sticken E, O'Connell G, Simms L, Rudd K, Stevenson M, Walele T. A comparative in vitro toxicity assessment of electronic vaping product e-liquids and aerosols with tobacco cigarette smoke. Toxicol In Vitro 2020; 66:104866. [PMID: 32353510 DOI: 10.1016/j.tiv.2020.104866] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 04/10/2020] [Accepted: 04/14/2020] [Indexed: 11/18/2022]
Abstract
The use of electronic vaping products (EVPs) continues to increase worldwide among adult smokers in parallel with accumulating information on their potential toxicity and relative safety compared to tobacco smoke. At this time, in vitro assessments of many widely available EVPs are limited. In this study, an in vitro battery of established assays was used to examine the cytotoxic (Neutral red uptake), genotoxic (In vitro micronucleus) and mutagenic (Bacterial reverse mutation) responses of two commercial EVPs (blu GO™ disposable and blu PLUS+™ rechargeable) when compared to smoke from a reference cigarette (3R4F). In total, 12 commercial products were tested as e-liquids and as aerosols. In addition, two experimental base liquids containing 1.2% and 2.4% nicotine were also assessed to determine the effect of flavour and nicotine on all three assays. In the bacterial reverse mutation (Ames) and in vitro micronucleus (IVM) assays, exposures to e-liquids and EVP aerosols, with and without nicotine and in a range of flavourings, showed no mutagenic or genotoxic effects compared to tobacco smoke. The neutral red uptake (NRU) assay showed significantly reduced cytotoxicity (P < .05) for whole undiluted EVP aerosols compared to tobacco smoke, which by contrast was markedly cytotoxic even when diluted. The reduced in vitro toxicological responses of the EVPs add to the increasing body of scientific weight-of-evidence supporting the role of high-quality EVPs as a harm reduction tool for adult smokers.
Collapse
Affiliation(s)
- R Wieczorek
- Reemtsma Cigarettenfabriken GmbH - Imperial Brands, Albert-Einstein-Ring 7, 22761 Hamburg, Germany
| | - G Phillips
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK.
| | - L Czekala
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK
| | - E Trelles Sticken
- Reemtsma Cigarettenfabriken GmbH - Imperial Brands, Albert-Einstein-Ring 7, 22761 Hamburg, Germany
| | - G O'Connell
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK
| | - L Simms
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK
| | - K Rudd
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK
| | - M Stevenson
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK
| | - T Walele
- Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, UK
| |
Collapse
|
27
|
An experimental aerosol air-agar interface mouse lymphoma assay methodology. Mutat Res 2020; 856-857:503230. [PMID: 32928375 DOI: 10.1016/j.mrgentox.2020.503230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 07/07/2020] [Accepted: 07/08/2020] [Indexed: 11/24/2022]
Abstract
This work investigates a completely novel and experimental concept of exposing L5178Y cells at the air-agar-interface to mainstream cigarette smoke aerosol (Kentucky reference 3R4F). This study highlights the associated challenges of combining a suspension cell line alongside an in vitro aerosol exposure system. To achieve a monolayer, cells were 'seeded' in a concentrated cell super-mix suspension onto an RPMI/agar-matrix -base. The resulting cell suspension media was adsorbed into the agar base leaving the L5178Y cells lightly suspended on the agar surface, approximating a monolayer. Cells were deemed supportable on the agar-matrix, viable and recoverable. Using Vitrocell VC 10 exposure system and the Ames 4 exposure module, L5178Y cells were successfully exposed to a dynamic cigarette smoke aerosol, recovered and assessed for mutant frequencies, using standard assay procedures. Method development included assessment of flowing air conditions, plating efficiency and recovery of L5178Y cells from the agar-matrix surface. Positive controls MMS and B[a]P were successfully incorporated into the agar-matrix and metabolic activation was achieved by S-9 incorporation into the same agar-base-matrix. B[a]P demonstrated metabolic activation and positive response, suggesting a clear cellular interaction with the agar-matrix. Whole smoke exposed cells in the presence of metabolic activation showed a clear dose response and increasing mutant frequencies, well in excess of the controls (air and incubator) and the global evaluation factor following a 2 or 3 day expression period. This experimental concept demonstrates that L5178Y cells can be exposed to cigarette smoke aerosol, using a completely novel and a previously untested approach. Although this work successfully demonstrates the approach is viable and cells can be plated and maintained on an agar-matrix, more optimisation and robustness assessment is required before it can be considered fully adapted and used alongside other whole aerosol methodologies for the assessment of cigarette smoke and other inhaled aerosols.
Collapse
|
28
|
Al-Saleh I, Elkhatib R, Al-Rajoudi T, Al-Qudaihi G, Manogarannogaran P, Eltabache C, Alotaibi A, Mummer AB, Almugbel S. Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. CHEMOSPHERE 2020; 249:126153. [PMID: 32058129 DOI: 10.1016/j.chemosphere.2020.126153] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Revised: 01/15/2020] [Accepted: 02/06/2020] [Indexed: 05/06/2023]
Abstract
In this study, we determined DNA damage and chromosome breakage (indicators of genotoxicity) and cell viability (an indicator of cytotoxicity) in human lymphoblastoid TK6 and Chinese hamster ovary (CHO) cells treated with 33 e-liquids using in vitro single cell gel (comet), micronucleus (MN), and trypan blue assays, respectively. We also measured the contents of nicotine, five phthalate esters, and DL-menthol in the e-liquids to examine their effects on DNA damage, chromosome breakage, and cell viability. Our chemical analyses showed that: (1) six e-liquids had nicotine ≥2-fold higher than the manufacture's label claim (2-3.5 mg); (2) both dimethyl- and dibutyl-phthalate levels were >0.1 μg/g, i.e., their threshold limits as additives in cosmetics; and (3) the DL-menthol contents ranged from 0.0003 to 85757.2 μg/g, with those of two e-liquids being >1 mg/g, the threshold limit for trigging sensory irritation. Though all the e-liquids induced DNA damage in TK6 cells, 20 resulted in cell viabilities ≤75%, indicating cytotoxicity, yet the inverse relationship between cell viability and DNA damage (r = -0.628, p = 0.003) might reflect their role as pro-apoptotic and DNA damage inducers. Fifteen e-liquids induced MN% in TK6 cells ≥3-fold that of untreated cells. Some of the increase in %MN might be false due to high cytotoxicity, yet six brands showed acceptable cell viabilities (59-71%), indicating chromosome damage. DNA damage and %MN increased when the TK6 cells were exposed to metabolic activation. The CHO cells were less sensitive to the genotoxic effects of the e-liquids than the TK6 cells. DL-menthol was found to be associated with decreased cell viability and increased DNA damage, even at low levels. We cannot dismiss the presence of other ingredients in e-liquids with cytotoxic/genotoxic properties since out of the 63 different flavors, 47 induced DNA damage (≥3-folds), and 26 reduced cell viability (≤75%) in TK6 cells.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Aminah Alotaibi
- National Center for Biotechnology and Genomic Research, King Abdulaziz City for Science and Technology, Saudi Arabia
| | - Abdulrahman Bin Mummer
- Biostatistics, Epidemiology & Scientific Computing Department, King Faisal Specialist Hospital & Research Centre, Saudi Arabia
| | - Saad Almugbel
- College of Medicine, Al-Imam Muhammed Ibn Saud Islamic University, Riyadh, Saudi Arabia
| |
Collapse
|
29
|
Ito S, Matsumura K, Ishimori K, Ishikawa S. In vitro long-term repeated exposure and exposure switching of a novel tobacco vapor product in a human organotypic culture of bronchial epithelial cells. J Appl Toxicol 2020; 40:1248-1258. [PMID: 32319113 PMCID: PMC7496418 DOI: 10.1002/jat.3982] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 03/25/2020] [Accepted: 03/25/2020] [Indexed: 12/16/2022]
Abstract
Next‐generation tobacco products and nicotine delivery systems such as heat‐not‐burn tobacco products and electronic cigarettes, the usage of which is expected to have a beneficial impact on public health, have gained popularity over the past decade. However, the risks associated with the long‐term use of such products are still incompletely understood. Although the risks of these products should be clarified through epidemiological studies, such studies are normally performed based on each product category, not product‐by‐product. Therefore, investigation of the risk on a product‐by‐product basis is important to provide specific scientific evidence. In the current study, we performed the 40‐day repeated exposure of in vitro human bronchial epithelial tissues to cigarette smoke (CS) or vapor from our proprietary novel tobacco vapor product (NTV). In addition, tissue samples exposed to CS were switched to NTV or CS exposure was stopped at 20 days to reflect a situation where smokers switched to NTV or ceased to smoke. All tissue samples were assessed in terms of toxicity, inflammation and transcriptomic alterations. Tissue samples switched to NTV and the cessation of exposure samples showed recovery from CS‐induced damage although there was a time‐course difference. Moreover, repeated exposure to NTV produced negligible effects on the tissue samples while CS produced cumulative effects. Our results suggest that the use of NTV, including switching to NTV from cigarette smoking, has fewer effects on bronchial epithelial tissues than continuing smoking. We carried out the 40‐day repeated exposure of in vitro bronchial epithelial tissues to cigarette smoke (CS) or vapor from novel tobacco vapor product (NTV) and intermediate switching from CS exposure to NTV exposure. Long‐term exposure to NTV resulted in negligible effect on the tissues. Moreover, the tissues that intermediately switched to NTV exposure showed recovery from CS‐induced damage similar to exposure cessation. These results implied that exposure to NTV showed few effects on bronchial epithelial tissues.
Collapse
Affiliation(s)
- Shigeaki Ito
- Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan
| | - Kazushi Matsumura
- Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan
| | - Kanae Ishimori
- Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan
| | - Shinkichi Ishikawa
- Scientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Japan
| |
Collapse
|
30
|
Fifteen Years of Airborne Particulates in Vitro Toxicology in Milano: Lessons and Perspectives Learned. Int J Mol Sci 2020; 21:ijms21072489. [PMID: 32260164 PMCID: PMC7177378 DOI: 10.3390/ijms21072489] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 03/10/2020] [Accepted: 04/01/2020] [Indexed: 12/13/2022] Open
Abstract
Air pollution is one of the world’s leading environmental causes of death. The epidemiological relationship between outdoor air pollution and the onset of health diseases associated with death is now well established. Relevant toxicological proofs are now dissecting the molecular processes that cause inflammation, reactive species generation, and DNA damage. In addition, new data are pointing out the role of airborne particulates in the modulation of genes and microRNAs potentially involved in the onset of human diseases. In the present review we collect the relevant findings on airborne particulates of one of the biggest hot spots of air pollution in Europe (i.e., the Po Valley), in the largest urban area of this region, Milan. The different aerodynamic fractions are discussed separately with a specific focus on fine and ultrafine particles that are now the main focus of several studies. Results are compared with more recent international findings. Possible future perspectives of research are proposed to create a new discussion among scientists working on the toxicological effects of airborne particles.
Collapse
|
31
|
Takanami Y, Kitamura N, Ito S. LC/MS analysis of three-dimensional model cells exposed to cigarette smoke or aerosol from a novel tobacco vapor product. J Toxicol Sci 2020; 45:769-782. [PMID: 33268677 DOI: 10.2131/jts.45.769] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
A novel tobacco vapor product (NTV) contains tobacco leaves and generates nicotine-containing aerosols using heating elements. Subchronic biological effects have been evaluated previously using three-dimensional bronchial epithelial model cells by repeated exposure to cigarette smoke (CS) and the NTV aerosols; however, the intracellular exposure characteristics have not been studied in detail. In this study, cells were initially exposed to an aqueous extract (AqE) of cigarette smoke (CS) at two concentration levels, and the cell lysate underwent untargeted analysis by LC-high resolution mass spectrometry to determine the exogenous compounds present in the cells. Among the thousands of peaks detected, four peaks showed a CS-dependency, which were reproducibly detected. Two of the peaks were nicotine and nicotine N-oxide, and the other two putative compounds were myosmine and norharman. The cells were then exposed to an AqE of CS in various combinations of exposure and post-exposure culture durations. Post-exposure culturing of cells with fresh medium markedly decreased the peak areas of the four compounds. The in-vitro switching study of CS to NTV aerosols was investigated by intermittently exposing cells to an AqE of CS four times, followed by exposure to either an AqE of CS, NTV aerosol or medium another four times. Switching to NTV reduced myosmine and norharman levels, which are known CS constituents. The results indicate that extracellular compounds inside cells reflect the exposure state outside cells. Thus, monitoring functional changes to cells in these exposure experiments is feasible.
Collapse
Affiliation(s)
| | | | - Shigeaki Ito
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc
| |
Collapse
|
32
|
In vitro mutagenicity of gas-vapour phase extracts from flavoured and unflavoured heated tobacco products. Toxicol Rep 2019; 6:1155-1163. [PMID: 31737489 PMCID: PMC6849343 DOI: 10.1016/j.toxrep.2019.10.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 10/02/2019] [Accepted: 10/04/2019] [Indexed: 11/23/2022] Open
Abstract
The in vitro mutagenic and genotoxic potential of Heated Tobacco Products (HTPs) has already been studied with the particulate phase and reported previously. This study has been designed to complement the in vitro assessment of the HTP and to determine whether the inclusion of potential flavourings would alter the in vitro response by testing the other phase of the aerosol, the gas-vapour phase (GVP). Both flavoured and unflavoured Neostik GVP samples did not show any sign of mutagenic activity in the Ames test but induced a mutagenic response in the mouse lymphoma assay (MLA), however, these responses were significantly less than those of the reference cigarette, 3R4F. The results demonstrated that GVP emissions of this HTP did not induce either new qualitative or quantitative mutagenic hazards compared to 3R4F, as assessed by the Ames test (no new responsive strains) and MLA (a lower mutagenic response), respectively. A statistical comparative analysis of the responses showed that the addition of flavourings that may thermally decompose under the conditions of use did not add to the in vitro baseline responses of the unflavoured Neostik.
Collapse
|
33
|
Mallock N, Pieper E, Hutzler C, Henkler-Stephani F, Luch A. Heated Tobacco Products: A Review of Current Knowledge and Initial Assessments. Front Public Health 2019; 7:287. [PMID: 31649912 PMCID: PMC6795920 DOI: 10.3389/fpubh.2019.00287] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 09/20/2019] [Indexed: 01/29/2023] Open
Abstract
The health risks of tobacco smoking have been documented in numerous studies and smoking rates have declined in developed countries over the last 50 years. Today, we know that cigarette smoking is the major cause of preventable deaths due to tobacco smoke induced diseases. As a consequence of an increased awareness of smoking-related health risks, heated tobacco products (HTPs) are marketed as reduced toxicant alternatives to conventional tobacco products. Manufacturers claim that levels of toxicants and hazardous compounds are significantly reduced, implying that inhalation of the modified aerosol is less harmful compared to conventional cigarettes. In this manuscript, previous assessments of HTPs are briefly summarized, including a short discussion on challenges with the adaption of standard analytical methods used for tobacco smoke. The reliability of analytical data is important for risk assessment approaches that are based on reduced toxicant exposure. In order to assess a putative reduction of health risks, an integrated study design is required that should include clinical studies and epidemiology data. One manufacturer applied for a classification as a Modified Risk Tobacco Product (MRTP) in the United States, based on extensive toxicological studies that have also been published. However, data are not yet sufficient for a reliable assessment or recognition of putatively reduced health risks. Challenges regarding a classification in Europe are also discussed briefly in this review.
Collapse
Affiliation(s)
- Nadja Mallock
- Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | - Elke Pieper
- Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | - Christoph Hutzler
- Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | - Frank Henkler-Stephani
- Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | - Andreas Luch
- Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| |
Collapse
|
34
|
Ito S, Taylor M, Mori S, Thorne D, Nishino T, Breheny D, Gaça M, Yoshino K, Proctor C. An inter-laboratory in vitro assessment of cigarettes and next generation nicotine delivery products. Toxicol Lett 2019; 315:14-22. [PMID: 31400404 DOI: 10.1016/j.toxlet.2019.08.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 07/16/2019] [Accepted: 08/06/2019] [Indexed: 02/07/2023]
Abstract
In vitro testing can facilitate the rapid assessment of next generation nicotine delivery products (NGPs) with comparisons to combustible tobacco products. In vitro assays for cytotoxicity and oxidative stress were employed at BAT (UK) and JT (Japan) to test total particulate matter (TPM) of a scientific reference cigarette and aerosol collected mass (ACM) of a commercially available E-cigarette and two tobacco heating products (THP). 3R4F TPMs were generated using the Health Canada intense (HCI) regimen, a modified regime (mHCI) for the THP ACMs and the CORESTA recommended method no. 81 for the E-cigarette ACM. Human lung cells were exposed to the test product TPM/ACMs at concentrations between 0-200 μg/ml followed by the employment of commercially available assays for endpoint analysis that included reactive oxygen species (ROS) generation, the glutathione ratio (GSH:GSSG), activation of the antioxidant response elements (ARE) and cellular viability. TPM/ACM nicotine concentrations were quantified using a UPLC-PDA technique. At both laboratories the 3R4F TPM induced significant and dose-dependent responses in all in vitro assays, whereas no significant responses could be measured for the NGP ACMs. In conclusion, both laboratories obtained comparable results across all endpoints therefore demonstrating the utility of the in vitro techniques combined with standardised test products to support the assessment of NGPs.
Collapse
Affiliation(s)
| | - Mark Taylor
- British American Tobacco, R&D, Southampton, UK.
| | - Sakura Mori
- Japan Tobacco Inc., R&D Group, Yokohama, Japan
| | | | | | | | | | - Kei Yoshino
- Japan Tobacco Inc., R&D Group, Yokohama, Japan
| | | |
Collapse
|
35
|
Thorne D, Leverette R, Breheny D, Lloyd M, McEnaney S, Whitwell J, Clements J, Bombick B, Gaça M. Genotoxicity evaluation of tobacco and nicotine delivery products: Part Two. In vitro micronucleus assay. Food Chem Toxicol 2019; 132:110546. [PMID: 31163219 DOI: 10.1016/j.fct.2019.05.054] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Revised: 05/06/2019] [Accepted: 05/29/2019] [Indexed: 11/26/2022]
Abstract
In this study, a variety of test matrices from tobacco and nicotine delivery products were assessed against a 3R4F Kentucky reference cigarette using the in vitro micronucleus assay. Testing was conducted using two Chinese hamster cell lines (CHO and V79), and a human lymphoblastoid cell line (TK6), in accordance with established guidelines. Total particulate matter (TPM) from a 3R4F Reference cigarette was compared to an electronic cigarette e-liquid, electronic cigarette TPM and TPM from a commercial tobacco heating product using a standard and an extended treatment condition with recovery period. Cells were assessed with 3R4F TPM prior to assessment of the other tobacco and nicotine product test matrices. These cell lines gave varied responses to 3R4F TPM with the most robust response using V79 cells. The use of an extended exposure/recovery period was seen to increase assay sensitivity for CHO and V79 cell lines but was less clear for TK6 cells. Negative responses were observed for all products except 3R4F across all treatment conditions in V79 cells. The most potent response to cigarette smoke was following extended treatment with recovery, suggesting this may be a more appropriate treatment for the future assessment of tobacco and nicotine product test matrices.
Collapse
Affiliation(s)
- David Thorne
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK.
| | - Robert Leverette
- RAI Services Company, 401 N. Main Street, Winston-Salem, NC, 27101, USA
| | - Damien Breheny
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| | - Mel Lloyd
- Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK
| | - Stephen McEnaney
- Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK
| | - James Whitwell
- Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK
| | - Julie Clements
- Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK
| | - Betsy Bombick
- RAI Services Company, 401 N. Main Street, Winston-Salem, NC, 27101, USA
| | - Marianna Gaça
- British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK
| |
Collapse
|
36
|
Czekala L, Simms L, Stevenson M, Tschierske N, Maione AG, Walele T. Toxicological comparison of cigarette smoke and e-cigarette aerosol using a 3D in vitro human respiratory model. Regul Toxicol Pharmacol 2019; 103:314-324. [DOI: 10.1016/j.yrtph.2019.01.036] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 01/25/2019] [Accepted: 01/28/2019] [Indexed: 10/27/2022]
|
37
|
Jaccard G, Djoko DT, Korneliou A, Stabbert R, Belushkin M, Esposito M. Mainstream smoke constituents and in vitro toxicity comparative analysis of 3R4F and 1R6F reference cigarettes. Toxicol Rep 2019; 6:222-231. [PMID: 30886823 PMCID: PMC6402302 DOI: 10.1016/j.toxrep.2019.02.009] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Revised: 02/19/2019] [Accepted: 02/24/2019] [Indexed: 11/26/2022] Open
Abstract
3R4F Kentucky reference cigarettes stock is depleting. 3R4F reference cigarettes have been widely used as monitor or comparator. 1R6F reference cigarettes are a suitable replacement for 3R4F on the basis of smoke chemistry and in vitro assays.
A new Kentucky reference cigarette, 1R6F, has been manufactured to replace the depleting 3R4F reference cigarette. The 3R4F Kentucky reference cigarettes have been widely used as monitor or comparator cigarettes for mainstream smoke analysis and in vitro and in vivo toxicological data of cigarettes and novel tobacco products. Both reference cigarettes were analyzed in the same laboratory during the same period of time with the goal of performing a comparison of 3R4F and 1R6F. On the basis of the results obtained from aerosol chemistry and in vitro assays, we consider that the 1R6F reference cigarette is a suitable replacement for the 3R4F reference cigarette as a comparator/monitor cigarette. Its specific use as a comparator for novel tobacco products was checked on the basis of a comparative test with the Tobacco Heating System 2.2 as an example.
Collapse
Affiliation(s)
- Guy Jaccard
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 3, CH-2000, Neuchâtel, Switzerland
| | - Donatien Tafin Djoko
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 3, CH-2000, Neuchâtel, Switzerland
| | - Alexandra Korneliou
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 3, CH-2000, Neuchâtel, Switzerland
| | - Regina Stabbert
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 3, CH-2000, Neuchâtel, Switzerland
| | - Maxim Belushkin
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 3, CH-2000, Neuchâtel, Switzerland
| | - Marco Esposito
- PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 3, CH-2000, Neuchâtel, Switzerland
| |
Collapse
|
38
|
Simms L, Clarke A, Paschke T, Manson A, Murphy J, Stabbert R, Esposito M, Ghosh D, Roemer E, Martinez J, Freiesleben J, Kim HK, Lindegaard T, Scharfe M, Vincze I, Vlachos P, Wigotzki D, Pollner G, Lutz R. Assessment of priority tobacco additives per the requirements of the EU Tobacco Products Directive (2014/40/EU): Part 1: Background, approach, and summary of findings. Regul Toxicol Pharmacol 2019; 104:84-97. [PMID: 30797887 DOI: 10.1016/j.yrtph.2019.02.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 02/14/2019] [Accepted: 02/16/2019] [Indexed: 10/27/2022]
Abstract
This paper is part of a series of 3 publications and describes the non-clinical and clinical assessment performed to fulfill the regulatory requirement per Art. 6 (2) of the EU Tobacco Products Directive 2014/40/EU; under which Member States shall require manufacturers and importers of cigarettes and roll-your-own tobacco containing an additive that is included in the priority list established by Commission Implementing Decision (EU) 2016/787 to carry out comprehensive studies. The Directive requires manufacturers and importers of cigarettes and Roll Your Own tobacco to examine for each additive whether it; contributes to and increases the toxicity or addictiveness of tobacco products to a significant or measurable degree; if it leads to a characterizing flavor of the product; if it facilitates inhalation or nicotine uptake, and if it results in the formation of CMR (carcinogenic, mutagenic and reprotoxic) constituents and if these substances increase the CMR properties of the respective tobacco product to a significant or measurable degree. This publication gives an overview on comprehensive smoke chemistry, in vitro toxicity, and human clinical studies commissioned by the members of the Priority Additives Tobacco Consortium to independent Contract Research Organizations (CROs) where the emissions of test cigarettes containing priority additives were compared to emissions emerging from an additive-free reference cigarette. Whilst minor changes in smoke chemistry parameters were observed when comparing emissions from test cigarettes with emissions from additive-free reference cigarettes, only two of the additives (sorbitol and guar gum) tested led to significant increases in a limited number of smoke constituents. These changes were not observed when sorbitol or guar gum were tested in a mixture with other priority additives. None of the priority additives resulted in increases in in vitro toxicity (Ames, Micronucleus, Neutral Red Uptake) or led to changes in smoking behavior or absorption (rate or amount) of nicotine measured during the human clinical study as compared to the additive-free reference cigarette.
Collapse
Affiliation(s)
- Liam Simms
- Imperial Tobacco, 121 Winterstoke Road, Bristol, BS3 2LL, United Kingdom.
| | - Anna Clarke
- Imperial Tobacco, 121 Winterstoke Road, Bristol, BS3 2LL, United Kingdom
| | - Thilo Paschke
- Japan Tobacco International SA, Rue Kazem Radjavi 8, 1202, Geneva, Switzerland
| | - Andrew Manson
- British American Tobacco, Globe House, Temple Place, London, United Kingdom
| | - James Murphy
- British American Tobacco, Research & Development, Regents Park Road, Southampton, SO158TL, United Kingdom
| | - Regina Stabbert
- Philip Morris International, Philip Morris Products SA, Rue des Usines 90, 2000, Neuchâtel, Switzerland
| | - Marco Esposito
- Philip Morris International, Philip Morris Products SA, Rue des Usines 90, 2000, Neuchâtel, Switzerland
| | - David Ghosh
- Philip Morris International, Philip Morris International Management SA, Avenue de Rhodanie 50, 1001, Lausanne, Switzerland
| | - Ewald Roemer
- TobToxConsulting, Imp. Blanchet-Dailleres 9, 1585, Cotterd, Switzerland
| | - Javier Martinez
- Japan Tobacco International SA, Rue Kazem Radjavi 8, 1202, Geneva, Switzerland
| | - Jarl Freiesleben
- Mac Baren Tobacco Company A/S, Porthusvej 100, DK-5700 Svenborg, Denmark
| | - Hyo-Keun Kim
- KT&G Research Institute, 30 Gajeong-ro, Yusong-gu, Daejeon, 34128, Republic of Korea
| | | | - Marc Scharfe
- LandewykTobacco S. A, 31 rue de Hollerich, 1741, Luxembourg B.P, 2202L-1022, Luxembourg
| | - Istvan Vincze
- Continental Tobacco Corporation, Continental Dohányipari Zrt, 1-3, Dohány utca Sátoraljaújhely, 3980, Hungary
| | | | - Diane Wigotzki
- Joh. Wilh. von Eicken GmbH, Drechslerstr. 1 - 3, 23556, Lübeck, Germany
| | - Gwen Pollner
- Pöschl Tabak GmbH & Co. KG, Dieselstrasse 1, 84144, Geisenhausen, Germany
| | - Rolf Lutz
- Philip Morris International, Philip Morris International Management SA, Avenue de Rhodanie 50, 1001, Lausanne, Switzerland
| |
Collapse
|
39
|
Ishikawa S, Matsumura K, Kitamura N, Takanami Y, Ito S. Multi-omics analysis: Repeated exposure of a 3D bronchial tissue culture to whole-cigarette smoke. Toxicol In Vitro 2019; 54:251-262. [PMID: 30291989 DOI: 10.1016/j.tiv.2018.10.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 08/09/2018] [Accepted: 10/01/2018] [Indexed: 02/02/2023]
Abstract
Cigarette smoke (CS) is a major risk factor in the development of chronic inflammatory lung diseases such as chronic obstructive pulmonary disease. A comprehensive investigation of the biological impacts of chronic CS exposure on lung tissue is therefore important for understanding the pathogenesis of lung disease. We used three-dimensional (3D) organotypic human bronchial tissue cultures and metabolomics, transcriptomics, and proteomics to investigate changes in biological processes affected by repeated whole-CS exposure. We found that CS perturbed central carbon metabolism in relation with oxidative stress responses. Epidermal growth factor receptor, which is involved in the early-stage pathogenesis of airway diseases, was identified as a key regulator of the perturbed processes. Proteomic analysis of proteins in the apical surface liquid of the 3D bronchial tissue cultures indicated that repeated whole-CS exposure induced alterations in the secretion of several known biomarkers of airway diseases, including mucins and matrix metalloproteinases. These findings are consistent with observations from lung disease patients. Overall, our results suggest that 3D bronchial tissue cultures can provide valuable information on tissue-specific alterations in biological processes induced by chronic exposure to CS.
Collapse
Affiliation(s)
- Shinkichi Ishikawa
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Kazushi Matsumura
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Nobumasa Kitamura
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Yuichiro Takanami
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Shigeaki Ito
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| |
Collapse
|
40
|
Hayes AW, Li R, Hoeng J, Iskandar A, Peistch MC, Dourson ML. New approaches to risk assessment of chemical mixtures. TOXICOLOGY RESEARCH AND APPLICATION 2019. [DOI: 10.1177/2397847318820768] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
| | - Roman Li
- Swiss Federal Institute of Aquatic Science and Technology (EAWAG), Dübendorf, Switzerland
- Philip Morris International (PMI) Research & Development, Neuchâtel, Switzerland
| | - Julia Hoeng
- Philip Morris International (PMI) Research & Development, Neuchâtel, Switzerland
| | - Anita Iskandar
- Philip Morris International (PMI) Research & Development, Neuchâtel, Switzerland
| | - Manuel C Peistch
- Philip Morris International (PMI) Research & Development, Neuchâtel, Switzerland
| | - Michael L Dourson
- Toxicology Excellence for Risk Assessment (TERA), Cincinnati, OH, USA
| |
Collapse
|
41
|
Munakata S, Ishimori K, Kitamura N, Ishikawa S, Takanami Y, Ito S. Oxidative stress responses in human bronchial epithelial cells exposed to cigarette smoke and vapor from tobacco- and nicotine-containing products. Regul Toxicol Pharmacol 2018; 99:122-128. [PMID: 30227175 DOI: 10.1016/j.yrtph.2018.09.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 08/13/2018] [Accepted: 09/12/2018] [Indexed: 12/15/2022]
Abstract
The use of novel tobacco- and nicotine-containing vapor products that do not combust tobacco leaves is on the rise worldwide. The emissions of these products typically contain lower numbers and levels of potentially harmful chemicals compared with conventional cigarette smoke. These vapor products may therefore elicit fewer adverse biological effects. We compared the effects of emissions from different types of such products, i.e., our proprietary novel tobacco vapor product (NTV), a commercially available heat-not-burn tobacco product (HnB), and e-cigarette (E-CIG), and a combustible cigarette in a human bronchial epithelial cell line. The aqueous extract (AqE) of the test product was prepared by bubbling the produced aerosol into medium. Cells were exposed to the AqEs of test products, and then glutathione oxidation, Nrf2 activation, and secretion of IL-8 and GM-CSF were examined. We found that all endpoints were similarly perturbed by exposure to each AqE, but the effective dose ranges were different between cigarette smoke and the tobacco- and nicotine-containing vapors. These results demonstrate that the employed assays detect differences between product exposures, and thus may be useful to understand the relative potential biological effects of tobacco- and nicotine-containing products.
Collapse
Affiliation(s)
- Satoru Munakata
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Kanae Ishimori
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Nobumasa Kitamura
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Shinkichi Ishikawa
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Yuichiro Takanami
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| | - Shigeaki Ito
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
| |
Collapse
|
42
|
Belushkin M, Esposito M, Jaccard G, Jeannet C, Korneliou A, Tafin Djoko D. Role of testing standards in smoke-free product assessments. Regul Toxicol Pharmacol 2018; 98:1-8. [DOI: 10.1016/j.yrtph.2018.06.021] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 06/28/2018] [Accepted: 06/30/2018] [Indexed: 12/22/2022]
|
43
|
Ansari SM, Lama N, Blanc N, Bosilkovska M, Donelli A, Picavet P, Baker G, Haziza C, Lüdicke F. Evaluation of Biological and Functional Changes in Healthy Smokers Switching to the Tobacco Heating System 2.2 Versus Continued Tobacco Smoking: Protocol for a Randomized, Controlled, Multicenter Study. JMIR Res Protoc 2018; 7:e11294. [PMID: 30143474 PMCID: PMC6128954 DOI: 10.2196/11294] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 07/25/2018] [Accepted: 07/25/2018] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND Tobacco harm reduction, substituting less harmful tobacco products for combustible cigarettes, is a complementary approach for smokers who would otherwise continue to smoke. The Philip Morris International (PMI) Tobacco Heating System (THS) 2.2 is a novel tobacco product with the potential to reduce the risk of harm in smokers compared to continued smoking of combustible cigarettes. It heats tobacco electrically in a controlled manner, never allowing the temperature to exceed 350°C, thereby preventing the combustion process from taking place and producing substantially lower levels of toxicants while providing nicotine, taste, ritual, and a sensory experience that closely parallels combustible cigarettes. Previous clinical studies have demonstrated reduced exposure to the toxicants (approaching the levels observed after quitting) for smokers who switched to THS 2.2, for three months. For adult smokers who would otherwise continue smoking combustible cigarettes, switching to THS 2.2 may represent an alternative way to reduce the risk of tobacco-related diseases. OBJECTIVE This study aimed to further substantiate the harm reduction potential of THS 2.2 by demonstrating favorable changes in a set of 8 coprimary endpoints, representative of pathomechanistic pathways (ie, inflammation, oxidative stress, lipid metabolism, respiratory function, and genotoxicity), linked to smoking-related diseases, in smokers switching from combustible cigarettes to THS 2.2. METHODS This study was a randomized, controlled, two-arm parallel group, multicenter ambulatory US study conducted in healthy adult smokers switching from combustible cigarettes to THS 2.2 compared with smokers continuing to smoke combustible cigarettes for six months. Subjects had a smoking history of at least ten years and did not intend to quit within the next six months. RESULTS Enrollment started in March 2015 and the trial was completed in September 2016. In total, 984 subjects were randomized (combustible cigarettes, n=483; THS 2.2, n=477), and 803 completed the study. The results are expected to be available in a subsequent publication in 2019. CONCLUSIONS In this paper, we describe the rationale and design for this clinical study that focused on the evaluation of THS 2.2's potential to reduce the risk of smoking-related diseases compared with that of combustible cigarettes. This study will provide insights regarding favorable changes in biological and functional endpoints informed by effects known to be seen upon smoking cessation. TRIAL REGISTRATION ClinicalTrials.gov NCT02396381; http://clinicaltrials.gov/ct2/show/NCT02396381 (Archived by WebCite at http://www.webcitation.org/71PCRdagP). REGISTERED REPORT IDENTIFIER RR1-10.2196/11294.
Collapse
Affiliation(s)
- S Michael Ansari
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Nicola Lama
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Nicolas Blanc
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Marija Bosilkovska
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Andrea Donelli
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Patrick Picavet
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Gizelle Baker
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Christelle Haziza
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| | - Frank Lüdicke
- Philip Morris International Research & Development, Neuchâtel, Switzerland
| |
Collapse
|
44
|
Crooks I, Neilson L, Scott K, Reynolds L, Oke T, Forster M, Meredith C, McAdam K, Proctor C. Evaluation of flavourings potentially used in a heated tobacco product: Chemical analysis, in vitro mutagenicity, genotoxicity, cytotoxicity and in vitro tumour promoting activity. Food Chem Toxicol 2018; 118:940-952. [PMID: 29879435 DOI: 10.1016/j.fct.2018.05.058] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Revised: 05/22/2018] [Accepted: 05/25/2018] [Indexed: 10/14/2022]
Abstract
We designed a novel tobacco-heating product (THP) that heats tobacco to release nicotine and aerosolised components, such as glycerol and tobacco volatiles from a tobacco rod (Neostik). Heating tobacco significantly reduces levels of combustion-derived toxicants in the aerosol compared to cigarette smoke. This study was conducted to determine whether the inclusion of potential flavourings in the THP would add to the levels of toxicants in the emissions or alter in vitro responses. Levels of measured toxicants were similar in the flavoured and unflavoured Neostik emissions and significantly less than emissions from the reference cigarette, 3R4F. No mutagenicity was observed with the Neostiks in the Ames test or in the mouse lymphoma assay. There was evidence of a weak genotoxic response in the in vitro micronucleus test using V79 cells from both Neostiks and these responses were less than 3R4F. They did not show tumour-promoting potential in the Bhas 42 cell transformation assay and were not cytotoxic in the Neutral Red uptake assay. 3R4F elicited toxic responses in all assays at significantly lower concentrations. The addition of flavourings to the Neostik tested did not alter the chemical profile of THP emissions or change in vitro responses relative to the unflavoured Neostik.
Collapse
Affiliation(s)
- Ian Crooks
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK.
| | - Louise Neilson
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Ken Scott
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Lorna Reynolds
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Tobi Oke
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Mark Forster
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Clive Meredith
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Kevin McAdam
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Chris Proctor
- Research and Development, British American Tobacco Investments Ltd., Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| |
Collapse
|
45
|
Yuki D, Takeshige Y, Nakaya K, Futamura Y. Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese smokers using a novel tobacco vapor product compared with conventional cigarettes and smoking abstinence. Regul Toxicol Pharmacol 2018; 96:127-134. [PMID: 29738810 DOI: 10.1016/j.yrtph.2018.05.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 04/27/2018] [Accepted: 05/01/2018] [Indexed: 01/20/2023]
Abstract
The objectives of this clinical study were to demonstrate a reduction in exposure to selected harmful and potentially harmful constituents (HPHCs), and to assess product use behavior, in Japanese healthy adult smokers who switched to a novel tobacco vapor product (NTV). 60 smokers were randomly assigned for 5 days to either (a) a group who switched to an NTV (n = 20), (b) a group who continued to smoke their own brand of conventional cigarettes (CC, n = 20) or (c) a smoking abstinence group (SA, n = 20). Fifteen biomarkers of exposure (BoEs) to 14 HPHCs and pyrene were measured at baseline, day 3 and 5. Product use behavior was assessed by measuring product consumption, nicotine uptake and puffing topography. During investigations, increases were observed in product consumption and total puff volume in NTV group subjects as compared to baseline. Additionally, nicotine uptake in the NTV group was approximately half that observed in the CC group. BoE values were significantly reduced in the NTV group as compared to those in the CC group. Significantly, the magnitude of the reduction in exposure to HPHCs observed in the NTV group (49-94%) was close to that observed for the SA group (39-95%).
Collapse
Affiliation(s)
- Dai Yuki
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Japan.
| | - Yuki Takeshige
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Japan
| | - Kyoko Nakaya
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Japan
| | - Yasuyuki Futamura
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Japan
| |
Collapse
|
46
|
Ishikawa S, Matsumura K, Kitamura N, Ishimori K, Takanami Y, Ito S. Application of a direct aerosol exposure system for the assessment of biological effects of cigarette smoke and novel tobacco product vapor on human bronchial epithelial cultures. Regul Toxicol Pharmacol 2018; 96:85-93. [PMID: 29730447 DOI: 10.1016/j.yrtph.2018.05.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 04/26/2018] [Accepted: 05/01/2018] [Indexed: 12/14/2022]
Abstract
Recent advancements in in vitro exposure systems and cell culture technology enable direct exposure to cigarette smoke (CS) of human organotypic bronchial epithelial cultures. MucilAir organotypic bronchial epithelial cultures were exposed, using a Vitrocell exposure system, to mainstream aerosols from the 3R4F cigarette or from a recently developed novel tobacco vapor product (NTV). The exposure aerosol dose was controlled by dilution flow and the number of products smoked; there were five exposure conditions for 3R4F smoke and three for NTV vapor. The amount of nicotine delivered to the tissues under each condition was analyzed and that of the total particulate matter (TPM) was estimated using nicotine data. The nicotine dose was similar for the two products at the highest dose, but the estimated TPM levels from the NTV were 3.7 times the levels from the 3R4F. Following 3R4F smoke exposure, a dose dependent increase was observed in cytotoxicity, cytokine secretion, and differential gene expression. However, no changes were detected in these endpoints following NTV vapor exposure, suggesting the biological effects of NTV vapor are lower than those of conventional combustible CS. Our study design, which includes collection of biological data and dosimetry data, is applicable to assessing novel tobacco products.
Collapse
Affiliation(s)
- Shinkichi Ishikawa
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Kazushi Matsumura
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Nobumasa Kitamura
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Kanae Ishimori
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Yuichiro Takanami
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| | - Shigeaki Ito
- Scientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama, Kanagawa 227-8512, Japan.
| |
Collapse
|